A Multicentric Phase II Trial Studying Efficacy of Doxorubicin Associated With Trabectedin (Yondelis) in First Line Treatment on Patients With Metastatic Leiomyosarcoma (Uterus or Soft Tissue) and/or Inoperable Relapse
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 110
- 试验地点
- 1
- 主要终点
- Disease control rate
研究概览
简要总结
Uterine leiomyosarcomas and soft tissues are rare tumors with a poor prognosis when metastatic or locally advanced. They have an average chemosensitivity mainly to doxorubicin, ifosfamide, cisplatin, gemcitabine and trabectedin but response rates in combination in first line does not exceed 55% for uterine leiomyosarcomas and 35% for leiomyosarcomas of soft tissue.
The trabectedin is a new cancer drug that has obtained marketing authorization after failure of anthracyclines and ifosfamide in the treatment of soft tissue sarcomas (STM) in Europe. It has especially shown efficacy in myxoid liposarcomas, leiomyosarcomas and synoviosarcoma.
This study aims to evaluate the usefulness of the combination of trabectedin with doxorubicin in first-line treatment of uterine or soft tissue leiomyosarcoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Metastatic leiomyosarcoma (uterus or soft tissue) in inoperable relapse with no previous chemotherapy
- •At least one measurable lesion according to RECIST criteria before inclusion. At least one of the target is in a none irradiated area
- •Aged >/= 18 years and physiological age </= 70 years
- •PS </= 2
- •Normal hematological function (Polymorphonuclear Neutrophils >/= 1500/mm3, platelets >/= 100 000/mm3)
- •Normal kidney function (creatinine < 1.5xN)
- •Creatinine phosphokinase </= 2.5xN
- •Normal hepatic function (total bilirubin </= 1xN; transaminase </= 2.5xN and alkaline phosphatase </= 1.5xN)
- •Cardiac function: normal echography and/or isotopic ventriculography (FR>30%, FEVG > 50%)
- •Patients able to procreate must use a birth control device during treatment and during 3 months after treatment for women; 5 months for men
- •Signed informed consent
- •Patient under affiliated to a system of care
排除标准
- •Any other histological type of uterus sarcoma (carcinosarcoma...) or soft tissue
- •Specific contraindication to the treatment
- •Previous or evolutive mental disease
- •Previous cancer
- •Symptomatic or known brain metastasis
- •Previous radiotherapy ont he only measurable lesion
- •Previous allograft or autograft
- •Known positive serology (HIV, HbC, HbS)
- •Pregnant or breastfeeding women
- •Impossibility to follow the treatment for geographical, social or mental reason
- •Patients under legal protection
研究组 & 干预措施
Soft tissue
干预措施: Doxorubicin (Drug)
Soft tissue
干预措施: Trabectedin (Drug)
Uterus
干预措施: Doxorubicin (Drug)
Uterus
干预措施: Trabectedin (Drug)
结局指标
主要结局
Disease control rate
时间窗: Assessed every 6 weeks from inclusion up to 6 months
Disease control rate (objective response + stability) as defined by RECIST criteria
次要结局
- Response rate(Assessed every 6 weeks from inclusion up to 6 months)
- Progression Free Survival(Assessed every 6 weeks from inclusion up to 12 weeks)